Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

NCT04553393 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden

Interventions

DRUG: Chidamide
DRUG: Decitabine
DRUG: Chidamide and Decitabine
BIOLOGICAL: Decitabine-primed Tandem CAR19/20 engineered T cells

Sponsor

Chinese PLA General Hospital